Topics

PubMed Journals Articles About "Roflumilast Bronchiectasis" RSS

13:37 EST 18th January 2020 | BioPortfolio

Roflumilast Bronchiectasis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Roflumilast Bronchiectasis articles that have been published worldwide.

More Information about "Roflumilast Bronchiectasis" on BioPortfolio

We have published hundreds of Roflumilast Bronchiectasis news stories on BioPortfolio along with dozens of Roflumilast Bronchiectasis Clinical Trials and PubMed Articles about Roflumilast Bronchiectasis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Roflumilast Bronchiectasis Companies in our database. You can also find out about relevant Roflumilast Bronchiectasis Drugs and Medications on this site too.

Showing "Roflumilast Bronchiectasis" PubMed Articles 1–25 of 57

Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry.

/objective: There are no large, multi-centre studies of Australians with bronchiectasis. The Australian Bronchiectasis Registry (ABR) was established in 2015 to create a longitudinal research platform. We aimed to describe the baseline characteristics of adult ABR participants and assess the impact of disease severity and exacerbation phenotype on quality of life (QoL).


Epidemiology of bronchiectasis in the UK: Findings from the British lung foundation's 'Respiratory health of the nation' project.

Key findings of this national survey of non-cystic fibrosis bronchiectasis epidemiology were that its prevalence, incidence and mortality have all increased over recent years; we estimate that around 212,000 people are currently living with bronchiectasis in the UK, very much higher than commonly quoted figures. Bronchiectasis is more common in females than males; 60% of diagnoses are made in the over-70 age group. Regional differences in prevalence, incidence, mortality, and hospital admission were identif...

Validation of the COPD Assessment Test (CAT) as an outcome measure in bronchiectasis.

Objective assessment of symptoms in bronchiectasis is important for research and in clinical practice. The COPD Assessment Test (CAT) is a short, simple assessment tool widely used in chronic obstructive pulmonary disease (COPD). The items included in the CAT are not specific to COPD and also reflect the dominant symptoms of bronchiectasis. We therefore performed a study to validate the CAT as an outcome measure in bronchiectasis.


Bronchiectasis and cough: An old relationship in need of renewed attention.

Bronchiectasis is an increasingly recognised respiratory condition with limited therapeutic options and a complex spectrum of clinical manifestations that invariably includes chronic cough. As the primary presentation of bronchiectasis in most cases, chronic cough and its mechanistic underpinnings are of central importance but remain poorly understood in this setting. Bronchiectasis is also increasingly identified as an underlying cause of chronic cough highlighting the interrelationship between the two con...

Prevalence and characterization of chronic rhinosinusitis in patients with non-cystic fibrosis bronchiectasis at a tertiary care center in the United States.

Chronic rhinosinusitis (CRS) is associated with bronchiectasis; however, this relationship has not been well studied in the United States (US) population. In this work we aimed to determine the prevalence of CRS among patients with bronchiectasis affiliated with a US tertiary medical center and identify which comorbid diseases are associated with the presence of CRS in patients with bronchiectasis.

Aetiology and disease severity are among the determinants of quality of life in bronchiectasis.

Quality of life (QoL) is known to be impaired in patients with bronchiectasis, which is generally attributed to exacerbations and chronic pulmonary symptoms. The aim of this study was to determine if aetiology and disease severity are associated with QoL in bronchiectasis.

How does Pseudomonas aeruginosa affect the progression of bronchiectasis?

Pseudomonas aeruginosa is one of the most common pathogens isolated from respiratory tract specimen in patients with bronchiectasis which is considered highly responsible for pathogenicity, progression and clinical outcomes of bronchiectasis.

Exercise capacity in patients with cystic fibrosis vs. non-cystic fibrosis bronchiectasis.

Bronchiectasis is associated with morbidity, low exercise capacity and poor quality of life. There is a paucity of data on exercise capacity using cardiopulmonary exercise test (CPET) in non-cystic fibrosis (CF) bronchiectasis. Our aim was to compare exercise capacity using CPET in CF and non-CF bronchiectasis patients.

Contemporary management of bronchiectasis in children.

: Bronchiectasis is increasingly recognised as a major cause of morbidity and mortality worldwide. It affects children of all ethnicities and socioeconomic backgrounds and represents a far greater burden than cystic fibrosis (CF). Bronchiectasis often begins in childhood and the radiological changes can be reversed, when mild, with optimal management. As there are limited paediatric studies in this field, current treatment approaches in children are based largely upon adult and/or CF studies. The recent est...

Predicting factors for chronic colonization of Pseudomonas aeruginosa in bronchiectasis.

About 25% of the patients with bronchiectasis are likely to develop a chronic colonization with Pseudomonas aeruginosa. A better understanding of predictors of acquiring Pseudomonas within the patient population may facilitate future focused research. The aim of this retrospective observational study was to investigate predicting factors for P. aeruginosa colonization in patients with bronchiectasis. This was a single-center retrospective cohort study using a bronchiectasis database which consisted of 211 p...

The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.

We compared the anti-inflammatory effects of phosphodiesterase type 4 (PDE4) inhibitor roflumilast with CHF6001, a novel PDE4 inhibitor designed for inhaled administration, using human alveolar macrophages (AM) and lung tissue explants models.

Mucoid Pseudomonas aeruginosa alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis.

Pseudomonas aeruginosa could acquire a mucoid phenotype due to mutations in mucA (mucoid Pseudomonas aeruginosa - mPA) that is a hallmark of poor prognosis in patients with bronchiectasis. Despite the higher prevalence of Pseudomonas aeruginosa in bronchiectasis, how mPA and non-mucoid Pseudomonas aeruginosa (non-mPA) phenotypes could affect viscoelastic properties of sputum is unknown. Our aim was to determine the relationship between Pseudomonas aeruginosa phenotypes isolation, the viscoelastic properties...

Non-CF Bronchiectasis as a Possible Indicator of a Primary Immunodeficiency: Diagnosis, Clinical Course, and Quality of Life in a Pediatric Cohort.

Non cystic fibrosis bronchiectasis (NCBE) is an increasingly recognized chronic, progressive respiratory disorder with significant morbidity also in children and adolescents.

Clinical Fingerprinting: A Way to Address the Complexity and Heterogeneity of Bronchiectasis in Practice.

The term bronchiectasis describes a complex and heterogeneous clinical syndrome which can be characterized by chronic respiratory symptoms and permanent dilation of the airways due to multiple causes. Understanding what "complex" and "heterogeneous" precisely means in the context of bronchiectasis disease is challenging. Complexity means that bronchiectasis has several components with "nonlinear dynamic interactions", whereas Heterogeneity indicates that not all the potential components that define bronchie...

Chronic obstructive pulmonary disease with and without bronchiectasis in Aboriginal Australians - a comparative study.

In this retrospective study we evaluated the demographic and clinical characteristic of adult Aboriginal Australian patients with a clinical diagnosis of COPD with and without bronchiectasis from the remote communities of the Northern Territory of Australia.

Extrapulmonary associations of health status in severe asthma and bronchiectasis: Comorbidities and functional outcomes.

Severe asthma and bronchiectasis are heterogeneous diseases that contribute to disability beyond the pulmonary system. The magnitude of the impact that these extrapulmonary features has on health-related quality of life (HRQoL) is unknown.

Coping and psychopathology in children with malignancy and bronchiectasis.

We aimed to evaluate the coping styles and social support perceived by the children with two different chronic diseases (cancer and bronchiectasis), their mothers' coping styles and compare them with a control group without any chronic physical or psychiatric disorder.

Duration of antibiotic therapy in non-cystic fibrosis bronchiectasis.

a)We conducted a review of the current evidence relating to antibiotic duration in the short and long-term management of non-cystic fibrosis bronchiectasis.

Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques.

Neutrophil elastase (NE) is a crucial marker of neutrophilic inflammation. We aimed to compare different techniques to detect active NE in sputum samples of 50 Bronchiectasis (BE) and 50 Cystic Fibrosis (CF) patients. Three methods including a ProteaseTag® Active NE Immunoassay (ELISA) and two enzymatic digestion assays (chromogenic -CS- and fluorogenic -FS- substrate) were compared. Results of active NE were also correlated with clinical data. The three methods provided statistically different values for ...

Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis.

Non-cystic fibrosis bronchiectasis (NCFB) is characterized by airway mucus accumulation and sputum production, but the role of mucus concentration in the pathogenesis of these abnormalities has not been characterized.

CAT (COPD ASSESSMENT TEST) In Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation. A Prospective Study.

Health-related Quality of Life (QoL) is one of the most important endpoints in bronchiectasis (BE). However, the majority of HRQoL questionnaires are time-consuming or not validated in BE. The COPD Assessment Test (CAT) in an easy-to-use questionnaire. The objective of this study was to perform a complete validation of CAT in BE.

Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesia.

Mucociliary clearance is a main defense mechanism of the airway and is impaired in ciliary dyskinesia. The objective of this study was to evaluate the prevalence of chronic rhinosinusitis (CRS) and its characteristics in bronchiectasis patients suspected of harboring ciliary dyskinesia.

Outpatient Parenteral Antimicrobial Treatment for Non-Cystic Fibrosis Bronchiectasis Exacerbations: A Prospective Multicentre Observational Cohort Study.

The recently published guidelines of the Spanish Society of Pulmonology and Thoracic Surgery encourage physicians to use outpatient antimicrobial therapy to treat exacerbations in patients with non-cystic fibrosis bronchiectasis (NCFB). The published literature on this topic, however, is scarce.

Low penetrance of antibiotics in the epithelial lining fluid. Experience from the use of inhaled antibiotics in patients with non CF-bronchiectasis.

Plasma drug concentrations, spectrum of antibacterial activity and minimum inhibitory concentration (MIC) had been widely considered as markers of the efficacy of antibiotics. Nonetheless, in several cases, antibiotics characterized by all these features were ineffective for the treatment of respiratory tract infections. A typical paradigm represented the case of patients with non-CF bronchiectasis who do not always benefit from antibiotics and thus experiencing increased sputum production, worse quality of...

A Woman With Dyspnea and Bronchiectasis.


Quick Search